Nemiralisib: Clinical Trials

8 completed. 4 Phase 1, 4 Phase 2.

By phase and status

Phase	Trials	Status
Phase 1	4	Completed 4
Phase 2	4	Completed 4

Follow Nemiralisib: new trials by email Literature Review of Nemiralisib trials Research Report on Nemiralisib

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics (PK) of Nemiralisib Nemiralisib, Itraconazole - Pulmonary Disease, Chronic Obstructive	Phase 1	Completed	GlaxoSmithKline	20	2018-01-17	2020-04-27
Safety, Tolerability and Pharmacokinetics (PK) Study of GSK2269557 in Healthy Subjects GSK2269557 500 µg, GSK2269557 750 µg - Pulmonary Disease, Chronic Obstructive	Phase 1	Completed	GlaxoSmithKline	12	2017-06-15	2019-08-19
Safety, Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Repeat Doses of Inhaled Nemiralisib in Patients With APDS/PASLI Nemiralisib - Activated PI3K-delta Syndrome	Phase 2	Completed	GlaxoSmithKline	5	2016-07-22	2021-06-18
A Study to Evaluate the Safety, Efficacy and Changes in Induced Sputum and Blood Biomarkers Following Daily Repeat Doses of Inhaled GSK2269557 in Chronic Obstructive Pulmonary Disease (COPD) Subjects With Acute Exacerbation GSK2269557, Placebo, DISKUS - Pulmonary Disease, Chronic Obstructive	Phase 2	Completed	GlaxoSmithKline	44	2015-11-04	2021-09-05
An Efficacy Study of GSK2269557 Added to Standard Care in Subjects With an Acute Exacerbation of Chronic Obstructive Pulmonary Disease GSK2269557, Placebo - Pulmonary Disease, Chronic Obstructive	Phase 2	Completed	GlaxoSmithKline	126	2015-03-31	2021-08-12
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Dose-Response Relationship of Multiple Doses of GSK2269557 Administered as a Dry Powder to Chronic Obstructive Pulmonary Disease (COPD) Patients GSK2269557 100 MCG, GSK2269557 500 MCG, PLACEBO - Pulmonary Disease, Chronic Obstructive	Phase 2	Completed	GlaxoSmithKline	64	2014-07-31	2018-10-11
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of the Dry Powder Formulation of GSK2269557 in Healthy Subjects GSK2269557, Placebo - Pulmonary Disease, Chronic Obstructive	Phase 1	Completed	GlaxoSmithKline	45	2013-01-09	2017-07-13
Study to Investigate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Single & Repeat Doses of GSK2269557 GSK2269557, GSK2269557 matching placebo - Asthma	Phase 1	Completed	GlaxoSmithKline	61	2011-07-24	2017-07-25

Conditions studied

Pulmonary Disease, Chronic Obstructive (6)  ·  Activated PI3K-delta Syndrome (1)  ·  Asthma (1)  ·  Respiratory Aspiration (1)

Sponsors

GlaxoSmithKline (8)

Countries

United Kingdom (4)  ·  Denmark (2)  ·  Belgium (1)  ·  Canada (1)  ·  Germany (1)  ·  Netherlands (1)  ·  Romania (1)  ·  Russia (1)  ·  United States (1)

NIH funding

2015 (2), 2014 (1), 2017 (1)